Lexicon Pharmaceuticals Inc. (LXRX)

3.56
NASDAQ : Health Technology
Prev Close 3.45
Day Low/High 3.44 / 3.75
52 Wk Low/High 1.12 / 11.51
Avg Volume 2.08M
Exchange NASDAQ
Shares Outstanding 106.27M
Market Cap 366.64M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Lexicon Pharmaceuticals To Present At Upcoming Investor Conference

Lexicon Pharmaceuticals To Present At Upcoming Investor Conference

THE WOODLANDS, Texas, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.

LXRX: Insiders Vs. Shorts

LXRX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Lexicon Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 19.07 "days to cover" versus the median component at 5.30.

Lexicon Pharmaceuticals To Present At Upcoming Investor Conference

Lexicon Pharmaceuticals To Present At Upcoming Investor Conference

THE WOODLANDS, Texas, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Publication Of Positive Data For Zynquista™ (Sotagliflozin) On Cardiorenal Clinical Biomarkers In Adults With Type 1 Diabetes

Lexicon Pharmaceuticals Announces Publication Of Positive Data For Zynquista™ (Sotagliflozin) On Cardiorenal Clinical Biomarkers In Adults With Type 1 Diabetes

Changes in Clinical Biomarkers Suggestive of Favorable Effects on Kidney Function in Patients with Type 1 Diabetes Results Recently Published in Diabetes Care THE WOODLANDS, Texas, Aug.

Interesting LXRX Call Options For September 20th

Interesting LXRX Call Options For September 20th

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the September 20th expiration.

Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results And Provides A Business Update

Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results And Provides A Business Update

THE WOODLANDS, Texas, July 31, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Date Change For Second Quarter 2019 Financial Results Conference Call And Webcast To July 31, 2019

Lexicon Pharmaceuticals Announces Date Change For Second Quarter 2019 Financial Results Conference Call And Webcast To July 31, 2019

THE WOODLANDS, Texas, July 30, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals To Host Second Quarter 2019 Financial Results Conference Call And Webcast On August 1, 2019

Lexicon Pharmaceuticals To Host Second Quarter 2019 Financial Results Conference Call And Webcast On August 1, 2019

THE WOODLANDS, Texas, July 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc.

First Week Of LXRX May 17th Options Trading

First Week Of LXRX May 17th Options Trading

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the May 17th expiration.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc.

Federman & Sherwood Announces Filing Of Securities Class Action Lawsuit Against Lexicon Pharmaceuticals, Inc.

Federman & Sherwood announces that on January 28, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of Texas against Lexicon Pharmaceuticals, Inc.

Oversold Conditions For Lexicon Pharmaceuticals (LXRX)

Oversold Conditions For Lexicon Pharmaceuticals (LXRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of February 15th Options Trading For Lexicon Pharmaceuticals (LXRX)

First Week Of February 15th Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the February 15th expiration.

Lexicon Pharmaceuticals Enters Oversold Territory (LXRX)

Lexicon Pharmaceuticals Enters Oversold Territory (LXRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Interesting LXRX Put And Call Options For November 16th

Interesting LXRX Put And Call Options For November 16th

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the November 16th expiration.

First Week Of January 2019 Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2019 expiration.

Lexicon Pharmaceuticals To Highlight Pipeline Progress At R&d Day On April 10, 2018

Lexicon Pharmaceuticals To Highlight Pipeline Progress At R&d Day On April 10, 2018

Company to Profile Key Assets Projected to Drive Long-Term Growth

First Week of May 18th Options Trading For Lexicon Pharmaceuticals (LXRX)

First Week of May 18th Options Trading For Lexicon Pharmaceuticals (LXRX)

Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the May 18th expiration.

Lexicon Pharmaceuticals Becomes Oversold (LXRX)

Lexicon Pharmaceuticals Becomes Oversold (LXRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D- (Sell)